NCT07722585CompletedPhase 1
A study to learn about how a new nurandociguat tablet is absorbed and processed in the body compared to an old tablet and how food affects the way the new tablet is absorbed and processed in the body
Source: EU CTIS (euclinicaltrials.eu) · Last updated 25 Sept 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 28 Jan 2026
- Start date
- 23 Jul 2026
- Lead sponsor
- Bayer AG
- Diseases
- Chronic kidney disease
- EU CT number
- 2025-524176-36-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 18
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CRS Clinical Research Services Berlin GmbH Coordinator of this site? Confirm its status | Berlin | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.